Apr 18 |
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
|
Apr 17 |
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
Apr 16 |
Why Regeneron (REGN) Could Beat Earnings Estimates Again
|
Apr 16 |
Regeneron to 'vigorously defend' against DOJ on Eylea pricing complaint
|
Apr 15 |
UPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulation
|
Apr 15 |
Regeneron to defend against DOJ complaint on drug-price manipulation
|
Apr 15 |
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation
|
Apr 15 |
Regeneron commits $500M to new venture capital fund
|
Apr 15 |
Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.
|
Apr 12 |
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
|